Logo

Pfizer’s Paxlovid (nirmatrelvir and ritonavir) Receives Health Canada’s Approval for the Treatment of COVID-19

Share this

Pfizer’s Paxlovid (nirmatrelvir and ritonavir) Receives Health Canada’s Approval for the Treatment of COVID-19

Shots:

  • Health Canada has authorized the use of Paxlovid (BID, for 5 days) for the treatment of mild-to-moderate COVID-19 in adults aged ≥18yrs.
  • The authorization is based on the P-II/III (EPIC-HR) trial to evaluate Paxlovid in non-hospitalized adults aged ≥18 with confirmed COVID-19 who are at high risk of progressing to severe illness including hospitalization or death. Additionally, the trial is ongoing in adults at low risk of hospitalization & who have been exposed to the virus through household contacts
  • Paxlovid is a SARS-CoV-2 main protease (Mpro) inhibitor. In Dec 2021, Pfizer collaborated with the Government of Canada to supply 1M treatment courses of Paxlovid in 2022

Ref: Newswire.Ca | Image: The Wall Street Journal

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions